University of Wisconsin–Madison

Igor Slukvin, PHD

Professor

Department

slukvin

Pathology and Laboratory Medicine

Contact Information

Igor Slukvin’s email

(608) 263-0058

Other web pages

Aligned research focus

Regenerative medicine, stem cells

Organ system/disease focus

Hematopoietic and vascular system/ blood cancer therapies

Research description

The main focus of research in my lab is to significantly advance the clinical use of stem cells through development of novel sources of hematopoietic stem cells, mature blood cells, mesenchymal and endothelial progenitors for transplantation, transfusion and cancer immunotherapy. We use integrative approaches, including genomics, proteomics and bioinformatics, to achieve the outlined goals and to understand important cellular and molecular events leading to mesoderm and blood cell development and diversification. We already developed a very efficient system for hematopoietic and endothelial differentiation of hES and iPS cells, and directed differentiation of hES cells toward red blood cells, dendritic cells, macrophages, osteoclasts and granulocytes. In addition, we defined the major cellular pathways leading to formation of blood cells and identified several novel hematoendothelial, hematopoietic and mesenchymal progenitors. Through comparative analysis of transcriptome and engraftment properties of these novel progenitors and fetal primitive blood cells as well as employing loss-of- and gain-on-function and lineage-tracing experiments, we expect to gain fundamental insights into molecular mechanisms leading to blood and endothelial cell development. These studies could ultimately revolutionize cellular therapies for blood cancer, hereditary blood and cardiovascular disease.

Selected references

D’Souza SS, Maufort J, Kumar A, Zhang J, Smuga-Otto K, Thomson JA, Slukvin II. GSK3β Inhibition Promotes Efficient Myeloid and Lymphoid Hematopoiesis from Non-human Primate-Induced Pluripotent Stem Cells. Stem Cell Reports. 2016 Feb 9;6(2):243-56. Induced Pluripotent Stem Cells. Stem Cell Reports. 2016 Feb 9;6(2):243-56.

Kang H, Minder P, Park MA, Mesquitta WT, Torbett BE, Slukvin II. CCR5 Disruption in Induced Pluripotent Stem Cells Using CRISPR/Cas9 Provides Selective Resistance of Immune Cells to CCR5-tropic HIV-1 Virus. Mol Ther Nucleic Acids. 2015 Dec 15;4:e268.

Elcheva I, Brok-Volchanskaya V, Slukvin I. Direct Induction of Hemogenic Endothelium and Blood by Overexpression of Transcription Factors in Human Pluripotent Stem Cells. J Vis Exp. 2015. Dec 3;(106).

Kang H, Minder P, Park MA, Mesquitta WT, Torbett BE, Slukvin II. CCR5 Disruption in Induced Pluripotent Stem Cells Using CRISPR/Cas9 Provides Selective Resistance of Immune Cells to CCR5-tropic HIV-1 Virus. Mol Ther Nucleic Acids. 2015. Dec 15;4.

Suknuntha K, Ishii Y, Tao L, Hu K, McIntosh BE, Yang D, Swanson S, Stewart R, Wang JY, Thomson J, Slukvin I. Discovery of survival factor for primitive chronic myeloid leukemia cells using induced pluripotent stem cells. Stem Cell Res. 2015. Nov;15(3):678-93.

Elcheva I, Brok-Volchanskaya V, Kumar A, Liu P,  Lee J, Tong L, Vodyanik M, Swanson S, Stewart R, Kyba M, Yakubov E, Cooke J, Thomson JA, and Slukvin I. Direct Induction of Hematoendothelial Program in Human Pluripotent Stem Cells by Transcriptional Regulators. Nat Commun. 2014 Jul 14;5:4372.